On Thursday, Shares of Alibaba Group Holding Limited (NYSE:BABA), gained 0.99% to $81.53.
EnterpriseDB (EDB), declared a contract with Aliyun, the cloud computing arm of Alibaba Group (NYSE: BABA) to provide a new generation of cloud database service in China.
Through the agreement, EDB’s Postgres Plus Advanced Server database will be accessible as a relational database-as-a-service on the Aliyun cloud computing platform. Aliyun offers a full suite of enterprise applications and, by partnering with EDB to add Postgres Plus, Aliyun customers can now enjoy a more diversified relational database suite.
EDB develops enterprise-class performance, security and compatibility enhancements for PostgreSQL, the world’s most advanced open source relational database. These enhancements are part of EDB’s Postgres Plus Advanced Server database. EDB also has developed database compatibility for Oracle to ease migrations and assist end users continue to use their Oracle skills and tools. The service with EDB Postgres Plus Advanced Server is accessible now and both companies will continue to collaborate to meet the growing needs of customers.
The Aliyun cloud is a ready-to-use, reliable, elastically scalable online database service. Aliyun has improved security, a performance monitoring system, and tools for backup, recovery and optimization.
Alibaba Group Holding Limited, through its auxiliaries, operates as an online and mobile commerce company in the People’s Republic of China and internationally. It operates Taobao Marketplace, an online shopping destination; Tmall, a third-party platform for brands and retailers; Juhuasuan, a group buying marketplace; Alibaba.com, an online wholesale marketplace.
Shares of Applied Materials, Inc. (NASDAQ:AMAT), declined -3.77% to $17.87, during its last trading session, hitting its lowest level.
Applied Materials, hosted its 2015 Analyst Meeting, providing an update to the company`s strategy for generating profitable growth. Applied executives showed how increasing R&D investments over the past several years are resulting in innovative new products that are enabling the key technology inflections in the semiconductor and display equipment industries. In addition, the company introduced its 2018 financial model targeting non-GAAP earnings per share of $2.00, assuming global wafer fab equipment spending in the $33.5 billion range.
The changes Applied began making to its product portfolio two years ago are now delivering results with strong new product traction. The company`s leadership businesses in transistor and interconnect have practiced noteworthyshare gains, while raised investments in etch and CVD resulted in growth that is outpacing the market. Recently, the company introduced two breakthrough products, the Centris(TM) Sym3(TM) Etch system and Olympia(TM) ALD system. Both are completely new equipment architectures, built from the ground up to provide customers with unprecedented capabilities in precision materials deposition and removal for building the most advanced logic and memory chip designs.
Applied Materials, Inc. provides manufacturing equipment, services, and software to the semiconductor, flat panel display, solar photovoltaic (PV), and related industries worldwide. The company’s Silicon Systems Group segment develops, manufactures, and sells a range of manufacturing equipment used to fabricate semiconductor chips or integrated circuits.
Finally, Baxalta Incorporated (NYSE:BXLT), ended its last trade with 1.58% gain, and closed at $31.46.
Nektar Therapeutics (NKTR) stated that partner Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, recently declared the publication of the complete data from the Phase II/III pivotal study and Phase I trial of BAX 855 in Blood, the journal of the American Society of Hematology. BAX 855 is Baxalta’s investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], a leading treatment for hemophilia A with more than 11 years of real-world patient experience.
Following on initial presentations of the data in 2014, the publication provides a comprehensive overview of the clinical trial results of BAX 855, which will be marketed in the United States under the brand name ADYNOVATE [Antihemophilic Factor (Recombinant), Pegylated] upon approval. The trial assessed the treatment’s safety and efficacy profiles for bleed prevention with a twice-weekly dosing plan, showing a mean half-life extension of 1.4- to 1.5-fold contrast with ADVATE. The positive study results were originally stated in August of 2014 and supported the company’s December 2014 submission for approval of BAX 855 to the United States Food and Drug Administration (FDA).
Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets a portfolio of products primarily for the treatment of hematology and immunology worldwide. It also offers other therapies for the treatments of bleeding disorders, and chronic and acute medical conditions, counting hemophilia A, hemophilia B, attained hemophilia, inhibitor treatments, primary immunodeficiency (PID), and alpha-1 antitrypsin deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
